hologic inc (HOLX) Key Developments
Hologic Inc. Announces Management Changes
Dec 9 13
Hologic Inc. announced that Stephen P. MacMillan has been named President and Chief Executive Officer, and a member of the Board of Directors. Mr. MacMillan succeeds Jack W. Cumming, who was named Chief Executive Officer in July 2013 and previously served in this capacity from 2001 to 2009. Prior to Stryker, Mr. MacMillan was a senior executive at Pharmacia Corporation.
Hologic Inc. Announces Board Changes
Dec 9 13
Hologic Inc. announced the appointment of Jonathan Christodoro and Samuel Merksamer to the company's Board of Directors, effective immediately pursuant to a settlement agreement with Carl C. Icahn. Mr. Christodoro and Mr. Merksamer are Managing Directors of Icahn Capital LP. Additionally, the company announced that it has engaged Dr. Burton Drayer as a scientific advisor to Hologic. Dr. Drayer currently serves as Chairman and Director of the Department of Radiology at The Mount Sinai Medical Center. Mr. Christodoro currently serves on the Board of Directors at Enzon Pharmaceuticals, Herbalife and Talisman Energy. Mr. Merksamer currently serves on the boards of CVR Refining, Ferrous Resources, CVR Energy, American Railcar Industries, Federal-Mogul Corporation, Viskase Companies, PSC Metals and Talisman Energy.
Hologic Inc., Annual General Meeting, Dec 09, 2013
Dec 3 13
Hologic Inc., Annual General Meeting, Dec 09, 2013., at 17:00 US Eastern Standard Time.
Hologic, Inc. Adopts Amendment to its By-Laws
Dec 3 13
Effective December 2, 2013, the Board of Directors of Hologic Inc. adopted an amendment to Section 1.4(a)(2) of the Company's Fourth Amended and Restated By-laws. The amendment extends the date by which nominations of persons for election to the Board may be submitted with respect to the company's 2014 annual meeting of stockholders to 5:00 p.m. EST on December 9, 2013.
Hologic to Showcase its Best-In-Class Imaging Portfolio at RSNA 2013
Nov 21 13
Hologic Inc. announced the groundbreaking imaging products it will highlight at the 99(th) Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place, Chicago from December 1(st) through 5(th). Hologic is dedicating a significant share of its RSNA exhibit to the clinical benefits of 3D mammography in breast cancer screening and diagnosis, and Hologic's recently introduced lower dose 3D mammography and 3D guided breast biopsy capabilities. Lower Dose 3D Mammography. Hologic's new C-View 2D software option is designed to generate a 2D image from a 3D mammography data set without the need for a separate 2D x-ray exposure. C-View software is designed to offer radiologists and patients a number of benefits including a reduction in x-ray exposures leading to shorter exam times (less than 4 second scan per view), and increased patient comfort from the shorter compression time. Hologic's 3D mammography exam using C-View software is a lower dose mammogram than the average U.S. 2D mammogrami and yet it includes all the benefits of a combined 2D and 3D mammography exam. 3D Guided Breast Biopsy. Hologic's Affirm 3D mammography biopsy option is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions not detected in 2D imaging or when using other modalities. This new biopsy technique is designed to provide numerous advantages over traditional stereotactic biopsy procedures, including faster lesion targeting and reduced patient procedure time. The Affirm system is pre-programmed for use with the company's Eviva and ATEC vacuum-assisted breast biopsy devices.